Press Enter to search · Esc to close
Semaglutide, exendin-4, and tirzepatide are pushing GLP-1 receptor agonists into hepatology and cardiology — while a fresh case report reminds us the safety ledger is still open.
Computational design is pushing peptide therapeutics into oncology, infectious disease, and antimicrobial resistance. The early signals are real — and the caveats matter.
A 109,000-patient meta-analysis sharpens the case that GLP-1 receptor agonists are cardiometabolic drugs, not just weight-loss tools — with concrete numbers on who actually benefits.
GLP-1 receptor agonists keep pushing into new clinical territory. Two 2025 papers — a modeling review for type 1 diabetes and a case report where semaglutide lit up brown fat on a PET scan — hint at what's next.
Semaglutide and liraglutide are being studied well past their metabolic origins. Early signals point to alcohol use disorder and diabetic blood-vessel protection — but the evidence is still uneven.
Semaglutide-class drugs are rewriting cardiometabolic medicine — and quietly accumulating a safety file that gym-goers should actually read.
Fresh cohort analyses say the perioperative picture is procedure-specific — reassuring at the hip, worrying at the shoulder — and shortages keep complicating the calculus.
GLP-1s aren't just a shred-cycle headline anymore. The next wave — liver-targeting combos, cardiovascular synergy with training, and oral delivery — is rewriting what these peptides can do.
As the GLP-1 class expands beyond weekly injections, three new studies sketch a more complicated risk-benefit map than the headline weight-loss numbers suggest.
Two fresh syntheses sharpen the picture of how the most-talked-about GLP-1 protects the heart — and where the evidence still has gaps.